🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Secondary stroke prevention in people with AF - published ⁦The Lancet Neurology⁩! fantastic team work valeria caso⁩ ⁦Lorenz Räber, MD PhD⁩ ⁦Urs Martin Fischer⁩ ⁦UCL Stroke Research⁩ ⁦Ashkan Shoamanesh⁩ ⁦European Stroke Org⁩ ⁦Stroke Research Center Bern⁩ authors.elsevier.com/a/1inIG5FFzL0D…

🫀 Does Alirocumab affect #platelet function in patients with #MI? ⤵️ 📌 Among pts. receiving DAPT in the PACMAN-AMI Trial, #Alirocumab had no significant effect on platelet reactivity In TH current issue 👉 thieme-connect.de/products/ejour… #PCSK9 #CardioTwitter Lorenz Räber, MD PhD

If you want to know more about pericardial effusion LAAC-related read our original research paper just published on Jacc Intv Lorenz Räber, MD PhD David Seiffge JACC Journals Cardiovascular Research Cluster (CVRC) sciencedirect.com/science/articl…

Thanks to Universität Bern, our recent The Lancet Neurology review on secondary stroke prevention in people with AF is now #openaccess! Urs Martin Fischer Lorenz Räber, MD PhD UCL Stroke Research valeria caso Virginia Cancelloni European Stroke Org World Stroke Org Stroke Research Center Bern European Stroke Master thelancet.com/journals/laneu…

Fantastic progress with the ELAPSE trial, an Schweizerischer Nationalfonds (SNF) supported IIT. Topic: LAAC/NOAC vs NOAC alone in breakthrough stroke patients.

Congratulations to sbaer for her successful PhD thesis defense @ Turku University, Finnland on the topic of CV imaging, led by Juhani Knuuti. Looking forward to have you back Insel Gruppe Cardiovascular Research Cluster (CVRC)

David Seiffge ELAPSE Urs Martin Fischer Lorenz Räber, MD PhD Stroke Research Center Bern Thomas Meinel European Stroke Master I strongly encourage all physicians to enroll AFib patients who had an ischemic stroke despite anticoagulant use into the ELAPSE - the RCT focusing on this population

🚨 New ELAPSE Trial Site Alert! 🚨 The Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne has officially opened today as the newest site in Switzerland for the ELAPSE trial and is now recruiting patients! Stroke Research Center Bern Lorenz Räber, MD PhD Urs Martin Fischer David Seiffge

Interested in incorporating routine CCT into your LAAO practice? Check out the latest expert consensus 📝 on the use of CCT post LAAO published today #JACCINT jacc.org/doi/10.1016/j.…

🚨 Rethink #Anomalous Aortic Origin of Coronary Artery #AAOCA + #interarterial course. 🚫No 'scissor-like' compression (unidirectional intramural compression by the aorta) 🚫Not all ‚malignant‘ (relevant) Lorenz Räber, MD PhD Marius Reto Bigler Swiss National Science Foundation EHJCaseReports Editor-in-Chief shorturl.at/VdL1x

New ESC hypertension guidelines: Class IIb for renal denervation in treatment resistant arterial hypertension despite RCT evidence from sham controlled trials. European Society of Cardiology PCRonline 🫀 #ESCLondon

New ESC CCS Guidelines on CCS. Longterm single antiplatelet tx with Clopidogrel now Class IB. Low dose Colchicine and GLP 1 RA lass IIb. PCRonline 🫀 European Society of Cardiology

New #ESC guidelines on AFIB. New Class IB recommendation for surgical LAAC in patients undergoing open heart surgery. No change for percutaneous LAAC despite Prague RCT (II b), unlike AHA /ACC Guidelines (IIa). Reflects the much lower uptake of LAAC in EU. PCRonline 🫀 European Society of Cardiology

AI based plaque characterization/quantification (AI QCT) of a #CCTA dataset (2000 patients referred for CAD evaluation in Turku, FIN) 7 YRS Fup treated medically shows that plaque burden and plaque composition accurately predicts future ACS events.Congratulations to sbaer

thanks Eric Topol for the interest in our plaque regression study with PCSK9i. The key point is that the level of plaque regression achieved in vessels is 2% (known already from main trial) but much more @ lesion level (5%) and at the most narrow spot of the vessel (10%).

Long-term effect of biodegradable vs durable polymer everolimus-eluting stents on neoatherosclerosis in ST-segment elevation myocardial infarction. Read the CONNECT trial in EHJ. doi.org/10.1093/eurhea… #STEMI #neoatherosclerosis #cardiotwitter European Society of Cardiology Journals European Society of Cardiology

Most viewed in the last 7 days from JAMA Cardiology: What are the effects of lowering low-density lipoprotein cholesterol in nonculprit coronary segments with advanced atherosclerotic features? ja.ma/3XHxSpz